StemCells, Inc. to Present at 2012 World Stem Cell Summit
NEWARK, Calif., Nov. 29, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development, will make a presentation on the Company's clinical development programs at the 2012 World Stem Cell Summit to be held December 3-5 at the Palm Beach County Convention Center, West Palm Beach, Florida. Dr. Tsukamoto is scheduled to speak during the Clinical Trial Update session to be held 10:30 a.m. to 12:00 p.m. Eastern Time on Tuesday, December 4. Dr. Tsukamoto also will be moderating a discussion on the topic "Unproven Stem Cell Therapies and Deceptive Claims: Hidden Dangers to Patients." This plenary discussion is scheduled to be held 9:00 to 10:00 a.m. Eastern Time on Tuesday, December 4.
StemCells, Inc. is a Silver Sponsor of the 2012 World Stem Cell Summit, which is planned by and for the global stem cell and regenerative medicine community and is the largest interdisciplinary stem cell conference. The goal of the 2012 World Stem CellSummit is to accelerate the discovery and development of lifesaving cures and therapies by bringing together a range of stakeholders to establish a supportive environment of regulation, legislation, financing, reimbursement and patient advocacy.
StemCells, Inc. will be co-hosting a reception on December 4, prior to the Summit's Stem Cell Action Awards Dinner. The Stem Cell Action Awards recognize dedicated individuals and organizations that have made distinguished contributions to the cause of stem cell research.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.
The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Rodney Young StemCells, Inc. Chief Financial Officer (510) 456-4128 Ian Stone Russo Partners (619) 308-6541